Erb-b2 receptor tyrosine kinase 2 (ERBB2; HER2) and erb-b2 receptor tyrosine kinase 3 (ERBB3; HER3) are mutated in a subset of cervical adenocarcinomas and these tumors may be susceptible to targeted therapies, and PTEN and AT-rich interaction domain 1A (ARID1A) alterations are also potential targets [18]. The gene discussed is ERBB3; the disease is cervical adenocarcinoma.